Source: STAT News | One of the biggest groundbreaking news to be heard this year is the potential of the anti inflammatory drug to reduce the risk of lung cancer.
“Patients who have a prior heart attack are very likely to have smoked cigarettes — and I knew because I’m an inflammation researcher, that they’re also at a high risk for lung cancer. So this particular study — though set up for atherosclerosis — turns the way people look at oncology, upside down”, says Novartis.
The therapy was initially designed for the cardiovascular patients, where a surprise side effect was observed, and that included the potential of this drug to effectively reduce the risk of lung cancer as well.
The study was carried out in 10000 individuals and 39% of them showed a reduced risk of lung cancer with the medium dosage of the drug, and 67% were seen to be in the safe zone with full dosage of the drug.
Inflammation is one of the body's first lines of defense against harmful invaders such as bacteria and other micro organisms. Inflammation can also occur in the lungs, for example, when a person smokes, inhales polluted air or is exposed to toxins such as silica and asbestos. Ans this is known to increase the risk of lung cancer.
This fascinating human finding has opened new dimensions in cancer treatment and prevention and is expected to be an effective treatment method in the future.
According to a study published in the journal Lancet, death from cancer was reduced by half in the group of people who received the highest dosage of this drug. The research team also noticed that, unlike canakinumab, this therapy directly prevents new lung cancers from developing and also slows lung cancer progression and invasiveness.
This invention is being considered as the first human data for an intervention of lung cancer. Researchers also say that further advancement and research is needed so that they can intervene in that inflammation, and get a better clinical outcome. Because a successful result can totally flip Oncology on its head.